ClinicalTrials.gg
CompletedNCT02286947Updated Mar 30, 2020Results posted

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

A Phase 2 interventional study of Eteplirsen in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Completed at 9 sites in United States. Open to male participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
7 Years to 21 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
4th of 11
24 · median 15
Started
2014
with 1 other
Phase 2
7 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 4th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 6th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 21 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Read the detailed description

This is an open-label, multi-center study to explore the safety and tolerability of eteplirsen injection in participants with advanced stage DMD with confirmed genetic mutations amenable to treatment by exon 51 skipping.

Participants will be evaluated for inclusion during a Screening/Baseline period of up to 4 weeks. Eligible participants will receive once weekly intravenous (IV) infusions of 30 mg/kg eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks).

Safety will be regularly assessed throughout the study via the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations.

03

Conditions studied

  • Muscular Dystrophy, Duchenne

Keywords

  • DMD
  • exon 51
  • dystrophin
  • dystrophy
  • eteplirsen
  • Duchenne
04

Who can participate

Ages eligible
7 Years to 21 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male 7 - 21 years of age
  • Diagnosis of DMD with a mutation that is amenable to exon 51 skipping, confirmed by a genetic report
  • Stable dose of oral for at least 24 weeks or has not received corticosteroids for at least 24 weeks
  • Non-ambulatory, or incapable of walking ≥300 meters on the 6-Minute Walk Test (6MWT).
  • Score of ≤4 on the Brooke Score for Arms and Shoulders.
  • Stable cardiac and pulmonary function
  • Use of for sexually active males throughout the study
  • Willing to provide consent and comply with the study

Exclusion criteria

Exclusion Criteria:

  • Use of any pharmacologic treatment (other than ) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids).
  • Previous treatment with SMT C1100/BMN 195 at any time.
  • Previous treatment with drisapersen (PRO051) within the last 6 months.
  • Participation in any other DMD interventional clinical study within 12 weeks
  • Major change in physiotherapy regimen within the past 3 months
  • Major surgery within 3 months
  • Presence of other illness
  • Use of an aminoglycoside antibiotic within 12 weeks or the need for this antibiotic or statin during study
  • Forced vital capacity % predicted [FVC % predicted] \<40%, or requiring daytime ventilation.
  • Require antiarrhythmic and/or antidiuretic therapy for heart failure.
  • Have a (LVEF) of \<40%.
  • Prior or ongoing medical condition that could adversely affect the safety of the patient, make it unlikely that the course of treatment would be completed, or impair the assessment of study results.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Eteplirsen 30 mg/kg

    Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.

    Drug: Eteplirsen

Interventions

  • Eteplirsen solution for IV infusion

    Also known as: AVI-4658, EXONDYS 51®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug (up to 100 weeks) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

    Time frame: From first dose of drug up to 100 weeks

Secondary outcomes

  1. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities

    Laboratory parameters included hematology, clinical chemistry, urinalysis and coagulation. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal findings. Incr=increase; LLN=lower limit of normal; ULN=upper limit of normal; GGT=gamma glutamyl transferase

    Time frame: Baseline up to 100 weeks

  2. Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs

    Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal vital sign findings.

    Time frame: Baseline up to 100 weeks

  3. Number of Participants With at Least One Potentially Clinically Significant Abnormalities in Physical Examinations

    Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Brief physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; and skin.

    Time frame: Baseline up to 100 weeks

  4. Number of Participants With Abnormalities in Electrocardiograms (ECGs)

    Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the patient was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. The Investigator reviewed the results of the centrally read ECG report and determined if the findings were clinically significant. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal ECG findings. msec=milliseconds; QTcF=QT interval corrected with Fridericia's method

    Time frame: Baseline up to 100 weeks

  5. Number of Participants With Abnormalities in Echocardiograms (ECHO)

    Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. Ejection fraction was noted. The Investigator reviewed the results of the ECHO report and determined if the findings were clinically significant. LEVF=left ventricular ejection fraction

    Time frame: Baseline up to 100 weeks

07

Results

Posted Feb 20, 2019

Participant flow

Participant flow — Overall Study
MilestoneEteplirsen 30 mg/kg
Started24
Completed22
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug (up to 100 weeks) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

Time frame:
From first dose of drug up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsEteplirsen 30 mg/kg
Number of Participants With Treatment Emergent Adverse Events24
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities

Laboratory parameters included hematology, clinical chemistry, urinalysis and coagulation. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal findings. Incr=increase; LLN=lower limit of normal; ULN=upper limit of normal; GGT=gamma glutamyl transferase

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
ParticipantsEteplirsen 30 mg/kg
Sodium: Decrease of 8 or more3
Sodium: Increase of 8 or more3
Potassium: Decrease of 1.1 or more2
Potassium: Increase of 1.0 or more2
Potassium: Value > 5.5 or < 3.01
Calcium: Decrease of 0.30 or more1
Glucose: Decrease of 3.1 or more1
Glucose: Increase of 3.2 or more6
Albumin: Value < LLN or > ULN4
Bilirubin: Incr of 10 or more1
Bilirubin: Value > 1.5 x ULN1
Alanine Aminotransferase: Value >= 2 x Baseline1
GGT: value > 3*Baseline or > ULN2
Lactate Dehydrogenase: Value >= 2 x Baseline1
Creatine Kinase: Value >= 2 x Baseline5
Hemoglobin: Value < LLN5
Hematocrit: Value < LLN7
Red Blood Cell: Value < LLN4
White Blood Cell: Value < LLN or > 1.5 x ULN5
Platelets: Value < 150 or < 2001
Neutrophils: Value > 1.5 x ULN or < 10007
Lymphocytes: Value < LLN6
Monocytes: Value < LLN14
Eosinophils: Value > 1.5 x ULN or < LLN2
Basophils: Value < LLN or > ULN2
Urine Protein: Value > 1+5
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities in Vital Signs

Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal vital sign findings.

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
ParticipantsEteplirsen 30 mg/kg
DBP: Less than 40 mmHG1
DBP: Greater than 90 mmHg12
SBP: Less than 80 mmHg4
SBP: Greater than 130 mmHG17
HR: Less than 50 beats per minute (bpm)1
HR: Greater than 130 bpm15
SecondaryNumber of Participants With at Least One Potentially Clinically Significant Abnormalities in Physical Examinations

Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Brief physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; and skin.

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With at Least One Potentially Clinically Significant Abnormalities in Physical Examinations
ParticipantsEteplirsen 30 mg/kg
Number of Participants With at Least One Potentially Clinically Significant Abnormalities in Physical Examinations23
SecondaryNumber of Participants With Abnormalities in Electrocardiograms (ECGs)

Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the patient was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. The Investigator reviewed the results of the centrally read ECG report and determined if the findings were clinically significant. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal ECG findings. msec=milliseconds; QTcF=QT interval corrected with Fridericia's method

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Electrocardiograms (ECGs)
ParticipantsEteplirsen 30 mg/kg
Heart Rate: >120 beats/minute6
QTcF: Increase of 60 or more msec1
SecondaryNumber of Participants With Abnormalities in Echocardiograms (ECHO)

Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. Ejection fraction was noted. The Investigator reviewed the results of the ECHO report and determined if the findings were clinically significant. LEVF=left ventricular ejection fraction

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Echocardiograms (ECHO)
ParticipantsEteplirsen 30 mg/kg
LEVF: <55%0
Fractional Shortening: <28%6

Adverse events

Collected over Baseline up to Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eteplirsen 30 mg/kg0/24 (0%)4/24 (16.7%)24/24 (100%)
Most frequent serious events
Most frequent serious events
EventEteplirsen 30 mg/kg
Extremity contractureMusculoskeletal and connective tissue disorders1/24
ScoliosisMusculoskeletal and connective tissue disorders1/24
CardiomyopathyCardiac disorders1/24
NephrolithiasisRenal and urinary disorders1/24
Most frequent other events
Showing 10 of 47
Most frequent other events
EventEteplirsen 30 mg/kg
NasopharyngitisInfections and infestations14/24
Back painMusculoskeletal and connective tissue disorders9/24
RashSkin and subcutaneous tissue disorders8/24
HeadacheNervous system disorders8/24
CoughRespiratory, thoracic and mediastinal disorders7/24
VomitingGastrointestinal disorders7/24
Upper respiratory tract infectionInfections and infestations6/24
ContusionInjury, poisoning and procedural complications6/24
Abdominal pain upperGastrointestinal disorders6/24
DiarrhoeaGastrointestinal disorders6/24

Baseline characteristics

Safety analysis population included all enrolled participants who received at least 1 dose of eteplirsen.

Age, Continuous
Age, Continuous(years)Eteplirsen 30 mg/kg
Mean12.9 ± 3.30
Sex: Female, Male
Sex: Female, Male(Participants)Eteplirsen 30 mg/kg
Female0
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eteplirsen 30 mg/kg
Hispanic or Latino3
Not Hispanic or Latino20
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eteplirsen 30 mg/kg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White21
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Eteplirsen 30 mg/kg
United States24
08

Study locations

9 sites
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Apr 2017, 29 months.

Results were first posted in Feb 2019, 1 year 9 months after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 29 months is close to that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2014
First posted
Nov 10, 2014
StartActual
Nov 2014
Primary completionActual
Apr 21, 2017
CompletionActual
Mar 23, 2018
Results first posted
Feb 20, 2019
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02286947
Responsible party
Sponsor
First posted
Nov 10, 2014
Start date
Nov 2014
Primary completion
Apr 21, 2017
Completion
Mar 23, 2018
Results posted
Feb 20, 2019
Last update
Mar 30, 2020

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion